NRX Pharmaceuticals (NRXP) Common Equity (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Common Equity data on file, last reported at -$13.8 million in Q1 2026.

• On a quarterly basis, Common Equity rose 45.15% year-over-year to -$13.8 million in Q1 2026; TTM through Mar 2026 was -$13.8 million, a 45.15% increase from a year earlier, with the FY2025 full-year figure at -$15.9 million, up 31.37% from the prior year.
• Common Equity for Q1 2026 stood at -$13.8 million, up from -$15.9 million in the prior quarter.
• Over the last five years, Common Equity for NRXP reached as high as $31.7 million in Q1 2022 and fell as low as -$35.6 million in Q2 2025.
• Historically, Common Equity has averaged -$7.7 million across 5 years, with a median of -$13.8 million in 2026.
• Across the five-year window, Common Equity surged 395.84% in 2022 and tumbled 5205.99% in 2024, its largest moves.
• Year by year, Common Equity stood at $7.4 million in 2022, then slumped by 258.36% to -$11.7 million in 2023, then slumped by 97.93% to -$23.2 million in 2024, then jumped by 31.37% to -$15.9 million in 2025, then increased by 13.41% to -$13.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$13.8 million in Q1 2026, -$15.9 million in Q4 2025, and -$25.8 million in Q3 2025.